Cover Image
市場調查報告書

&s;神經生長因子:開發中產品分析

Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 367840
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
&s;神經生長因子:開發中產品分析 Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H2 2016
出版日期: 2016年07月27日 內容資訊: 英文 61 Pages
簡介

本報告提供以&s;神經生長因子為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

&s;神經生長因子 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥開發企業

  • Amgen Inc.
  • Astellas Pharma Inc.
  • Chiesi Farmaceutici SpA
  • 爬蔓植物製藥
  • Krenitsky Pharmaceuticals Inc.
  • MedImmune, LLC
  • NsGene A/S
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Staidson (Beijing) Biopharmaceuticals Co., Ltd.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0413TDB

Summary

Global Markets Direct's, 'Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H2 2016', provides in depth analysis on Beta Nerve Growth Factor (Beta NGF or NGF) targeted pipeline therapeutics.

The report provides comprehensive information on the Beta Nerve Growth Factor (Beta NGF or NGF), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Beta Nerve Growth Factor (Beta NGF or NGF)
  • The report reviews Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Beta Nerve Growth Factor (Beta NGF or NGF)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Beta Nerve Growth Factor (Beta NGF or NGF) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Beta Nerve Growth Factor (Beta NGF or NGF) Overview
    • Therapeutics Development
  • Beta Nerve Growth Factor (Beta NGF or NGF) - Products under Development by Stage of Development
  • Beta Nerve Growth Factor (Beta NGF or NGF) - Products under Development by Therapy Area
  • Beta Nerve Growth Factor (Beta NGF or NGF) - Products under Development by Indication
  • Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Beta Nerve Growth Factor (Beta NGF or NGF) - Products under Development by Companies
  • Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Beta Nerve Growth Factor (Beta NGF or NGF) - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • Astellas Pharma Inc.
    • Chiesi Farmaceutici SpA
    • Fujimoto Pharmaceutical Corporation
    • Krenitsky Pharmaceuticals Inc.
    • MedImmune, LLC
    • NsGene A/S
    • Pfizer Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Staidson (Beijing) Biopharmaceuticals Co., Ltd.
  • Beta Nerve Growth Factor (Beta NGF or NGF) - Drug Profiles
    • AS-288640100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fasinumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fulranumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate NGF for Undisclosed Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KP-544 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-7352 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NsG-0202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RBM-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Target NGF for Undisclosed Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Neurotrophic Keratitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tanezumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Beta Nerve Growth Factor (Beta NGF or NGF) - Dormant Projects
  • Beta Nerve Growth Factor (Beta NGF or NGF) - Discontinued Products
  • Beta Nerve Growth Factor (Beta NGF or NGF) - Featured News & Press Releases
    • May 02, 2016: Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain
    • Mar 31, 2016: Janssen Announces Discontinuation of Fulranumab Phase 3 Development Program in Osteoarthritis Pain
    • Mar 23, 2015: Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab
    • Mar 12, 2012: FDA Panel Recommends Development Of NGF Inhibitors
    • Feb 09, 2011: CeNeRx Receives FDA IND Approval For CXB909
    • Dec 27, 2010: FDA Halts Development Of Regeneron's Pain Drug
    • Jul 19, 2010: Pfizer Suspends Chronic Pain Studies In Tanezumab Clinical Trial Program
    • Jun 23, 2010: Pfizer Suspends Osteoarthritis Clinical Program For Tanezumab
    • May 12, 2010: Regeneron Provides Initial Data On REGN475
    • Feb 16, 2010: Pending Results of Phase Ib Trial for Nsg0202 for Alzheimer's Disease in 2010
    • Nov 15, 2008: Nsgene Has Announced That Six Patients with Alzheimer's Disease Have Now Been Implanted with Its Novel Biodelivery Product Nsg 0202
    • Oct 24, 2008: Krenitsky Pharmaceuticals Wants Out Of Deal With Keryx
    • Dec 17, 2007: NsGene First To Implant Genetically Modified Cells Into Patients' Brains
    • Dec 12, 2007: Nsgene A/S Begins Phase Ib Clinical Trial with Nsg0202 for the Treatment of Alzheimer's Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Amgen Inc., H2 2016
  • Pipeline by Astellas Pharma Inc., H2 2016
  • Pipeline by Chiesi Farmaceutici SpA, H2 2016
  • Pipeline by Fujimoto Pharmaceutical Corporation, H2 2016
  • Pipeline by Krenitsky Pharmaceuticals Inc., H2 2016
  • Pipeline by MedImmune, LLC, H2 2016
  • Pipeline by NsGene A/S, H2 2016
  • Pipeline by Pfizer Inc., H2 2016
  • Pipeline by Regeneron Pharmaceuticals, Inc., H2 2016
  • Pipeline by Staidson (Beijing) Biopharmaceuticals Co., Ltd., H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top